Votes: IL HB1779 | 2021-2022 | 102nd General Assembly

Bill Title: Amends the Illinois Insurance Code. Provides that a group or individual policy of accident and health insurance or managed care plan amended, delivered, issued, or renewed on or after January 1, 2022 shall include coverage for biomarker testing. Provides that biomarker testing shall be covered and conducted in an efficient manner to provide the most complete range of results to the patient's health care provider without requiring multiple biopsies, biospecimen samples, or other delays or disruptions in patient care. Provides that biomarker testing must be covered for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when the test is supported by medical and scientific evidence. Provides that when coverage of biomarker testing for the purpose of diagnosis, treatment, or ongoing monitoring of any medical condition is restricted for use by health insurers, nonprofit health service plans, or health maintenance organizations, the patient and prescribing practitioner shall have access to a clear, readily accessible, and convenient processes to request an exception, and the process shall be made readily accessible on the insurer's website. Defines "biomarker" and "biomarker testing". Makes conforming changes in the State Employees Group Insurance Act of 1971, the Counties Code, the Illinois Municipal Code, the School Code, the Health Maintenance Organization Act, the Limited Health Service Organization Act, the Voluntary Health Services Plans Act, and the Illinois Public Aid Code.

Spectrum: Moderate Partisan Bill (Democrat 50-10)

Status: (Passed) 2021-07-30 - Public Act . . . . . . . . . 102-0203 [HB1779 Detail]

Text: Latest bill text (Chaptered) [HTML]

Voting Records

ChamberVoteDateYeaNayNVAbsTotalResultSourceView
SenateThird Reading in Senate2021-05-255801059PassedLinkView
HouseThird Reading in House2021-04-14112001113PassedLinkView


Social Comments on IL HB1779

feedback